What are the opening hours?

Monday 9am - 7pm Tuesday 9am - 7pm Wednesday 9am - 7pm Thursday 9am - 7pm Friday 9am - 7pm Saturday 9am - 7pm

SmartQR Technologies Pvt Ltd

Home
India
Pune
SmartQR Technologies Pvt Ltd

Specializes in developing innovative and cutting-edge healthcare solutions to enhance public health.

25/05/2026

HPV is one of the most common infections linked to cervical cancer. But research increasingly shows that infection alone does not determine risk.
Genetics also plays a role.

Studies suggest that genetic differences can influence how the body responds to HPV, including immune response, persistence of infection and progression to cervical abnormalities.
This is why 2 individuals with similar HPV exposure may experience very different outcomes.

As women’s healthcare moves toward more preventive and personalized care, molecular and genetic insights are becoming increasingly important in supporting proactive clinical decisions.

Understanding risk earlier can lead to better monitoring, earlier action and more informed care.

18/05/2026

GLP drugs are becoming one of the most prescribed treatments for metabolic conditions in India.
And for good reason.

India carries one of the highest numbers of diabetes, obesity and cardiovascular disease cases in the world and GLP-based therapies offer real promise.

But there is a gap that does not get talked about enough.
Not every patient responds to GLP treatment the same way.

Genetic variation means the same drug, at the same dose, can produce very different outcomes from one patient to the next.

Yet most prescriptions are still written without this information.

The tools to change this already exist. Pharmacogenomic testing can tell us, before treatment begins, how a patient's body is likely to respond to a specific drug.

The next step for metabolic care in India is moving from standardised prescribing to precision prescribing, where treatment decisions are guided by the patient's own biology.

That is the gap SmartQR is working to close.

11/05/2026

GLP drugs are among the most talked-about treatments in metabolic medicine today and for good reason.

But here is what the research is increasingly pointing to: not every patient responds to GLP-based treatment the same way. And the reason, in large part, comes down to genetics.

Studies in pharmacogenomics have shown that genetic variations directly influence how a patient's body metabolises GLP medication, determining how quickly the drug takes effect, how well it works and what side effects a patient may experience.

This means that two patients on the same drug, at the same dose, can have very different outcomes because of their DNA.

DNA-based testing has the potential to change this.
By understanding a patient's genetic profile before treatment begins, doctors can make more informed decisions, such as selecting the right drug, at the right dose, for the right patient from day 1.

At SmartQR, this is exactly what we are working towards.
Source: PMC/NIH - Pharmacogenomics and personalised medicine in clinical practice

27/04/2026

Most cardiac risks develop silently.

By the time a patient walks into a clinic with symptoms, the underlying risk has often been present for years; undetected, unaddressed.

At the OPD level, a doctor typically has access to blood pressure readings, visible symptoms and family history.

What is often missing is the most important piece of information: the patient’s genetic cardiac risk profile.

SmartCardio changes that.

It is a genetic test designed to help doctors make more informed treatment decisions, right from the very first visit.

By analysing key genes that influence how the body responds to cardiac medication, SmartCardio enables doctors to select the right drug, at the right dose, for the right patient before treatment even begins.

Here is a simple example.

A patient visits the OPD after a heart stent procedure.
The doctor plans to prescribe Clopidogrel. Without genetic testing, there is no way to know if the patient can properly activate the drug.

With SmartCardio, a poor metaboliser is identified early, an alternative is prescribed and the risk of clot formation is avoided.

That is the practical value of precision diagnostics at the OPD level.

20/04/2026

Millions of Indians are on cardiac medication today: statins, blood thinners, antihypertensives and more.
These are some of the most commonly prescribed drugs in the country.

But here is a question that does not get asked often enough: how does a doctor know if the drug they have prescribed is actually working the way it should for that specific patient?

The answer lies in genetics.

Every patient's body processes medication differently. Genetic factors influence the rate at which a drug is metabolised, how effectively it works and whether it causes side effects.

The same dose that is effective for one patient may be ineffective or even harmful for another.
This variability in drug response is increasingly being recognised in clinical practice.

And in cardiology, where treatment decisions can be critical, understanding a patient's genetic profile before prescribing can make a significant difference.

Precision starts with understanding the patient.
That is what InGene is built for.

13/04/2026

Much of your cardiac risk may already be encoded in your DNA..

Research has long established a strong connection between genetics and cardiovascular health.
Studies suggest that up to 50% of cardiac risk may be influenced by hereditary factors yet for most patients, genetic testing is still not part of routine cardiac care.

Beyond risk, genetics also plays a significant role in how patients respond to treatment.
The same cardiac medication can work very differently from one person to the next, depending on their genetic profile.

This is not an exception; it is increasingly being recognised as the norm in clinical practice.

Genomic screening has the potential to identify cardiac risk before symptoms even appear.

The science is clear and the tools exist. What's needed now is wider adoption at the clinical level.

At SmartQR, this is the gap we are working to close: bringing genetic insights into everyday cardiac care.

Source: PMC/NIH – Genetics, its role in preventing the pandemic of coronary artery disease

07/04/2026

Health today is about making the right decisions at the right time.

This World Health Day, the focus is on building a future where care is more precise, more proactive and more personal.

At SmartQR, we are working towards this shift by bringing genetic insights into everyday clinical decisions.

This helps doctors understand how each patient may respond to treatment before it begins.

Because better treatments start with better understanding.

Right insight. Right care. Right time.

01/04/2026

A defining step towards the future of healthcare.

SmartQR Genomics is proud to be awarded the prestigious opportunity to establish a Pharmacogenetic Testing Setup for Cardiology at a Prestigious Government Medical College in Maharashtra.

First of its kind project in Maharashtra Medical Education.

This advanced setup enables:
* Precise, personalized medication for cardiac patients
* Better understanding of drug sensitivity & response
* A strong foundation for medical research & student learning

With a single device supporting multiple test kits, this solution is designed to scale across departments—making it a truly future-ready diagnostic ecosystem for Genetics.

This initiative marks a significant leap in Precision Diagnostics in Pharmacogenetics, setting new benchmarks in patient care and clinical decision-making.

A visionary move by GMC Team.

A transformative milestone by SmartQR Genomics.

More than 3+ Government Medical Colleges are using Ingene .

23/03/2026

𝗧𝘄𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗺𝗮𝘆 𝗿𝗲𝗰𝗲𝗶𝘃𝗲 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻, 𝘆𝗲𝘁 𝘁𝗵𝗲𝗶𝗿 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗰𝗮𝗻 𝗯𝗲 𝘃𝗲𝗿𝘆 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁.

One critical reason? Genetic variation.

Variants in the CYP2C19 gene can significantly affect how the body processes antiplatelet drugs like Clopidogrel. In some patients, the medication may not work as expected, increasing the risk of treatment failure.

Pharmacogenetic (PGx) testing helps identify these differences early, moving cardiology toward a more personalized approach.

𝗧𝗵𝗲 𝗜𝗻𝗚𝗲𝗻𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 & 𝗦𝗺𝗮𝗿𝘁𝗖𝗮𝗿𝗱𝗶𝗼:
• Efficient Analysis: The InGene Device enables rapid genetic testing in clinical settings.
• Targeted Insights: The SmartCardio panel evaluates genetic variants specifically linked to cardiovascular drug response.
• Informed Decisions: Helping clinicians choose the right treatment for the right patient, right from the start.

Discover how we’re advancing personalized cardiovascular care at SmartQR.

16/03/2026

Did you know that two people who take the exact same heart medicine, but get completely different results?

It all comes down to your DNA. Just like our genes determine our eye color, they also control how our bodies process medicine.

For some people, certain heart medications (like blood thinners) might not work as well because of their genetic makeup. This can leave them at risk, even if they are following their doctor's orders.

This is where SmartCardio helps. By using a simple genetic test, doctors can:
- See exactly how your body will react to a drug.
- Pick the right medicine from day 1.
- Avoid "trial and error" with your heart health.

Personalised medicine means better care and peace of mind.

Address

Sr No 213, Rishi House, Plot 65, Hindustan Estate, Kalyaninagar
Pune
411006

Opening Hours

Monday	9am - 7pm
Tuesday	9am - 7pm
Wednesday	9am - 7pm
Thursday	9am - 7pm
Friday	9am - 7pm
Saturday	9am - 7pm

Telephone

+918956276294

Website

http://www.smartqr.co.in/

Alerts

Be the first to know and let us send you an email when SmartQR Technologies Pvt Ltd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to SmartQR Technologies Pvt Ltd:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Business
Claim ownership or report listing

Want your business to be the top-listed Health & Beauty Business in Pune?